A Phase 2/3 interventional study of PLB1001 and Temozolomide in Glioblastoma, sponsored by Beijing Pearl Biotechnology Limited Liability Company. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Beijing Pearl Biotechnology Limited Liability Company · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Glioblastoma with a site in China — 73 open to participants now, 80 under way, 7 of them phase 3. Glioblastoma · China.
Among the 142 studies in Glioblastoma with a site in China, this one is the 31st largest by enrollment of the 127 interventional ones that give a count, is one of 4 that started in 2018, is one of 2 in phase 2/3, reaches primary completion later than 1 of the 79 other live ones, and was the 85th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →73 of the 142 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Jecho Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Xiangya Hospital of Central South University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 58 · Phase 3 13
First in 2008; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 36 across the 127 interventional studies, 100 across the 15 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 142 have an industry lead sponsor. The 10 most frequent:
Beijing Pearl Biotechnology Limited Liability Company is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Beijing Pearl Biotechnology Limited Liability Company has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
15 of the studies in Glioblastoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538128Huashan HospitalEvaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | 2026-11-27 |
| NCT06368934Huashan HospitalSub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | 2026-12 |
| NCT05842746Peking Union Medical College HospitalElemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | 2026-12 |
| NCT03005132Shanghai 10th People's HospitalIntegrative Analysis of Human Glioblastoma Multiforme | 2026-12 |
| NCT04959500Sun Yat-sen UniversityNewly Diagnosed Glioblastoma | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 142 studies in Glioblastoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are:
Participants will
84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene will be randomly divided into group A (receive vebreltinib) or group B ( receive investigator choose), and the randomize ratio will be 1:1, patients in group A will receive PLB1001 300mg Bid, 28days/cycle. Patients in group B will receive temozolomide (100-150mg/m2/d, 7 days 1 to7 and days 15 to 22 of each 28-day cycle ) or cisplatin+etoposide(cisplatin:80-100mg/m2/3 days, 28days/cycle; etoposide:100mg/m2/d, 3days, 28 days/cycle).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 300mg of PLB1001 twice daily in cycles of 4 weeks duration until death or adverse event(AE) leading to discontinuation
Drug: PLB1001
Investigators can choose one of two treatments 1. Dose density of temozolomide:100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle 2. Cisplatin combined with etoposide:Cisplatin,80-100mg/m2/3 days,28 days/cycle.etoposide, 100mg/m2/d,3 days,28 days/cycle
Drug: Temozolomide · Drug: Cisplatin combined with Etoposide
PLB1001 is a capsule in the form of 300mg,twice daily.
Also known as: Vebreltinib
100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle
Drug pages: Cisplatin · Etoposide
Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
Overall survival(OS)
Overall survival is defined as the time(in months)from random to the date of death.
Time frame: 5 years
Objective Response Rate Evaluated by Investigator(ORR)
Objective response rate will be determined according to response assessment in neuro-oncology(RANO).
Time frame: 5 years
Progression Free Survival evaluated by Investigator(PFS)
Progression Free Survival is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD or death due to any cause.
Time frame: 5 years
Quality of Life Assessment EORTC-QLQ-C30
The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item scales and single-item measures. These include the Physical Functioning Scale and four more functional scales (role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status / QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and difficulties). Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." The method for scoring these scales is: 1. Estimate the average of the items that contribute to the scale; this is the raw score. 2. Use a linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.
Time frame: 5 years
Karnofsky Performance Status score
improved is defined as KPS increases \>10 after treatment; worsen is defined as KPS decreases \>10; stable is defined as KPS changes ≤10.
Time frame: 5 years
Quality of Life Assessment EORTC-QLQ-BN20
The EORTC-QLQ-BN20 covers future uncertainty, visual disorder, motor dysfunction, communication deficit, headache, seizures, drowsiness, hair loss, itching, difficulty with bladder control, and weakness of both legs. Patients respond by self-report, with most items rated on a 4-point scale, from 1 "not at all" to 4 "very much", except for the two global health status/quality of life items, which are measured on a 7-point Likert scale ("very poor" through "excellent"). The method for scoring these scales is: 1. Estimate the average of the items that contribute to the scale; this is the raw score. 2. Use a linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2018 to primary completion in Apr 2023, 53 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vebreltinib
Beijing Pearl Biotechnology Limited Liability Company